$25.04−$0.5300 (−2.07%) on the dayAs of the close; data may be delayed.
VCYT price, last 12 months
$60.49$24.00
Daily closes over the last 260 trading sessions: −40.0%. Highest close $60.49 on , lowest $24.00 on . Market data may be delayed.
Key stats
Previous close
$25.57
Open
$25.87
Day range
$24.95 – $26.63
52-week range
$21.91 – $60.91
Volume
1.9M
Avg volume (20 days)
3M
Market cap
$2.0B
Performance
1W+3.5%
1M−45.3%
3M−39.3%
6M−44.1%
YTD−40.2%
1Y−36.9%
vs S&P 500, 1Y−42.1 pts
Technicals and fundamentals
About Veracyte, Inc.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
Chart VCYT with indicators, scan for setups and get alerts
This page is open to everyone. A free ScanPro account adds the interactive parts, along with watchlists, paper trading with simulated money and the Academy's quizzes.
A full VCYT chart with indicator overlays, pattern markers and daily, weekly or intraday bars.
Scans of a whole index or list with 72 named conditions, 26 chart setups or a formula of your own.
Alerts and notifications when one fires on a stock you watch, on delayed market data.
Daily range (ATR)11.3%average true range, % of price
52w low $21.9152w high $60.91
Where price sits today against its own history. A description, not a forecast.
Valuation
P/E (trailing)16.00.64x Services median (24.9)
P/E (forward)16.2
PEG—
Price / sales3.48
Price / book1.41
EV / EBITDA—
P/E since Jun 114.9 – 42.5
Company figures as of Nov 20, 2026.
Analysts
ConsensusBuy1.7 on 1 (strong buy) to 5 (strong sell)
Analysts10
Average target$41.60+65.2% from today
Price targets are opinions and tend to lean optimistic.
Earnings
Next results, expectedaround Feb 24, 2027 (in 95 days)A year after its Feb 25, 2026 results release; the last came Nov 4, 2026. An estimate from its SEC filings, not a date the company announced.
Seasonality
-4.8
J
-8.8
F
-8.6
M
-6.2
A
+6.8
M
+8.9
J
+3.4
J
+5.5
A
-1.3
S
+5.0
O
+21.3
N
-5.3
D
Average return in each calendar month, Oct 31, 2021 to Oct 31, 2026. 6 years is 6 observations a month: too few to call a pattern, so read it as history, not a calendar to trade.
Year by year
Year
J
F
M
A
M
J
J
A
S
O
N
D
Year
2026
−10
−4
−12
+2
+41
+27
−21
−7
+7
+9
+19%
2025
+15
−24
−15
+3
−13
+2
−13
+29
+13
+5
+31
−11
+6%
2024
−9
−6
−6
−12
+6
+4
+11
+31
+8
−1
+27
−8
+44%
2023
+6
−2
−9
+2
+14
−2
+8
−4
−15
−7
+24
+7
+16%
2022
−26
−9
−1
−26
−14
+13
+32
−23
−19
+21
+38
−14
−42%
2021
+3
−13
−1
−11%
Each year's monthly returns in %, the observations behind the averages. The last column compounds the year's months; a year the history only partly covers is faded.
Financials
As reported in the company's SEC filings. Latest: Q3 FY2026, ended Sep 30, 2026.
Free shows the latest quarter, the latest year and the last 12 months. Plus shows every period and the growth figures.See Plus
Figures are as each 10-Q and 10-K reported them, in the company's own fiscal calendar, not restated later. A company that changes how it reports a line can make one period look out of step with the rest. Growth compares the same period a year earlier and is left blank when the year before was a loss. Banks and insurers report no gross profit, so rows they don't file are left out. Every filing on SEC EDGAR
The company announced positive Phase III trial results showing its Decipher test can predict treatment benefit, providing Level 1B evidence for a clinically important treatment decision. This expands the test's clinical utility, supports potential for broader adoption, and strengthens its competitive positioning in prostate cancer diagnostics. The findings also build on recent NCCN guideline incorporation and support ongoing prospective trials.
The company is showcasing significant clinical research validation of its Decipher test through multiple presentations at a major medical conference, demonstrating growing adoption and clinical utility in prostate cancer treatment decisions. This represents positive momentum for the company's diagnostic platform and market positioning.
Ranked #1 with Q2 2026 adjusted EPS of 54 cents beating estimates by 25.6%, revenues beating by 4.1%, and consistent earnings beats over trailing four quarters with 41.8% average surprise. Estimated 2026 earnings growth rate of 8.4% shows solid performance.
Veracyte holds a Zacks Rank #1 with exceptional earnings beat consistency (average 41.8% surprise over trailing four quarters), solid revenue growth, and an estimated 2026 earnings growth rate of 8.4%.
Veracyte holds a Zacks Rank #1 (Strong Buy) with impressive earnings beat of 25.6% and revenue beat of 4.1% in Q2 2026, plus consistent earnings outperformance with an average surprise of 41.8% over trailing four quarters.
Tone is the news provider's automated reading of each article for this stock. It describes the article, not what the price will do.
Figures describe the past, not what the price will do next. Educational tools, not investment advice.